Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: ERN, ERP

HALOZYME REPORTS SECOND QUARTER 2022 FINANCIAL AND OPERATING RESULTS


Closed Antares Pharma Acquisition, Accelerating High Growth Drug Delivery Leadership and Projected to be Accretive to Revenue for Full Year 2022

Second Quarter Revenue Increased 12% YOY to $152.4 million, with GAAP Diluted Earnings per Share of $0.16 and Non-GAAP Diluted Earnings per Share of $0.53

Record Second Quarter Royalty Revenue Increased 86% YOY to $85.3 million

Raising 2022 Revenue Guidance to $655 Million to $685 Million, up from $530 Million to $560 Million, Representing 48%-55% Growth over Reported 2021 Revenue     

SAN DIEGO, Aug. 9, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today reported its financial and operating results for the second quarter ended June 30, 2022 and provided an update on its full year 2022 financial guidance and recent corporate activities.

"As we report our strong second quarter results and execute our plans to continue to deliver sustained high growth, I have never been more excited about the future and potential of Halozyme. We see strong ENHANZE momentum with our Wave 2 products DARZALEX SC and Phesgo and with recent positive Phase III study results for efgartigimod SC and Tecentriq SC, two of our four Wave 3 launch products with the potential for launch 2023-2025. As planned, we project at least six Phase 2 or Phase 3 study starts in 2022," said Dr. Helen Torley, president and chief executive officer of Halozyme. "The acquisition of Antares Pharma enhances our revenue growth and durability, adding a commercialized, broadly licensable autoinjector platform and two innovative commercial products in the large and growing testosterone replacement therapy market."

Recent Partner Highlights:

Recent Corporate Highlights:

Second Quarter Financial Highlights

Financial Outlook for 2022

The Company is raising its financial guidance for 2022 which was last provided on May 10, 2022, as a result of the recent close of the Antares Pharma transaction and strong year-to-date results. For the full year 2022, the Company expects:

The Company's earnings per share guidance does not consider the impact of potential future share repurchases.

Table 1. 2022 Financial Guidance



Guidance Range

Prior Range

Net Revenue


$655 to $685 million

$530 to $560 million

Operating Income


$240 to $265 million

$350 to $380 million

GAAP Net Income


$170 to $195 million

$270 to $295 million

Non-GAAP Net Income


$295 to $320 million1

$290 to $315 million

GAAP Diluted EPS


$1.20 to $1.35

$1.90 to $2.05

Non-GAAP Diluted EPS


$2.10 to $2.251

$2.05 to $2.20

Webcast and Conference Call

Halozyme will host its Quarterly Update Conference Call for the second quarter ended June 30, 2022 today, Tuesday, August 9, 2022 at 4:30 p.m. ET/1:30 p.m. PT. The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast and additional documents related to the call, please visit the "Investors" section of www.halozyme.com.

About Halozyme

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients. Having touched more than 600,000 patient lives in post-marketing use in five commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare and Chugai Pharmaceutical.

Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The Company has a commercial portfolio of proprietary products including XYOSTED®, TLANDOtm and NOCDURNA® and partnered commercial products and ongoing product development programs with industry leading pharmaceutical companies including Teva Pharmaceutical, Covis Pharma, Pfizer and Idorsia Pharmaceuticals.

Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.

For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.

Note Regarding Use of Non-GAAP Financial Measures

In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), this press release and the accompanying tables contain certain Non-GAAP financial measures. The Company reports Non-GAAP net income and Non-GAAP diluted earnings per share in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The Company calculates Non-GAAP net income and Non-GAAP diluted earnings per share excluding share-based compensation expense, amortization of debt discount, debt extinguishment expense and certain adjustments to income tax expense. Reconciliations between GAAP and Non-GAAP financial measures are included at the end of this press release.  The Company evaluates other items of income and expense on an individual basis and considers both the quantitative and qualitative aspects of the item, including (i) its size and nature, (ii) whether or not it relates to the Company's ongoing business operations and (iii) whether or not the Company expects it to occur as part of Halozyme's normal business on a regular basis. Non-GAAP financial measures do not have any standardized meaning and are therefore unlikely to be comparable to similarly titled measures presented by other companies. These Non-GAAP financial measures are not meant to be considered in isolation and should be read in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that the Company may exclude for purposes of its Non-GAAP financial measures; and the Company may in the future cease to exclude items that it has historically excluded for purposes of its Non-GAAP financial measures. Halozyme considers these Non-GAAP financial measures to be important because they provide useful measures of the operating performance of the Company, exclusive of factors that do not directly affect what the Company considers to be its core operating performance, as well as unusual events. The Non-GAAP measures also allow investors and analysts to make additional comparisons of the operating activities of the Company's core business over time and with respect to other companies, as well as assessing trends and future expectations. The Company uses Non-GAAP financial information in assessing what it believes is a meaningful and comparable set of financial performance measures to evaluate operating trends, as well as in establishing portions of our performance-based incentive compensation programs.

Safe Harbor Statement

In addition to historical information, the statements set forth in this press release include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance (including the Company's financial outlook for 2022) and expectations for future growth, profitability, total revenue and royalty revenue, net and operating income and earnings-per-share and to repurchase shares under its share repurchase program. Forward-looking statements regarding the Company's ENHANZE® drug delivery technology may include the possible benefits and attributes of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and facilitating more rapid delivery and administration of larger volumes of injectable medications through subcutaneous delivery. Forward-looking statements regarding the Company's business may include potential growth and receipt of royalty and milestone payments driven by our partners' development and commercialization efforts, potential new clinical trial study starts and product launches, the size and growth prospects of our partners' drug franchises, potential new collaborations and collaborative targets and regulatory review and potential approvals of new partnered or proprietary products and the Company's plans to develop new formulations of its API for longer intellectual property protection. These forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning and involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including unexpected levels of revenues, expenditures and costs, unexpected delays in the execution of the Company's share repurchase program,  risks associated with executing the Antares acquisition, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the proposed acquisition will not be realized, unexpected results or delays in the growth of the Company's business, or in the development, regulatory review or commercialization of new formulations of the Company's API or its partnered or proprietary products, including any potential delays caused by the current COVID-19 global pandemic, regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.

Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@antarespharma.com

Dawn Schottlandt / Claudia Styslinger
Argot Partners
212-600-1902
Halozyme@argotpartners.com

Footnotes:
1. Reconciliations between GAAP reported and non-GAAP financial information and adjusted guidance measures are provided at the end.

 

Halozyme Therapeutics, Inc

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except per share amounts)








Three Months Ended

 June 30,


Six Months Ended

June 30,



2022


2021


2022


2021

Revenues:









Royalties


$        85,340


$            45,778


$    154,945


$       82,701

Product sales, net


46,300


30,360


68,440


52,126

Revenues under collaborative agreements


20,725


60,317


46,259


90,650

Total revenues


152,365


136,455


269,644


225,477

Operating expenses:









Cost of sales


33,943


23,018


49,865


41,237

Amortization of intangibles


11,403


?


11,403



Research and development


15,483


8,069


27,336


17,078

Selling, general and administrative


57,476


12,321


71,310


23,380

Total operating expenses


118,305


43,408


159,914


81,695

Operating income


34,060


93,047


109,730


143,782

Other income (expense):









Investment and other (expense) income, net


(945)


221


(447)


497

Inducement expense related to convertible note


?


?


?


(20,960)

Interest expense


(3,104)


(1,752)


(4,863)


(3,717)

Net income before income taxes


30,011


91,516


104,420


119,602

Income tax expense


7,326


58


21,627


249

Net income


$        22,685


$            91,458


$      82,793


$     119,353










Net income per share:









Basic


$             0.16


$                0.64


$           0.60


$           0.85

Diluted


$             0.16


$                0.62


$           0.58


$           0.81










Shares used in computing net income per share:









Basic


137,937


142,487


137,798


140,201

Diluted


142,216


147,624


141,795


148,096

 

Halozyme Therapeutics, Inc

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands)




June 30,
2022


December 31,
2021

ASSETS





Current assets:





Cash and cash equivalents


$           90,932


$          118,719

Marketable securities, available-for-sale


118,428


622,203

Accounts receivable, net and contract assets


189,368


90,975

Inventories, net


97,615


53,908

Prepaid expenses and other current assets


45,595


40,482

Total current assets


541,938


926,287

Property and equipment, net


37,091


8,794

Prepaid expenses and other assets


26,283


13,414

Goodwill


199,481


?

Intangible assets, net


976,097


?

Deferred tax assets, net


?


155,434

Restricted cash


500


500

Total assets


$      1,781,390


$       1,104,429






LIABILITIES AND STOCKHOLDERS' EQUITY





Current liabilities:





Accounts payable


$           12,232


$              1,541

Accrued expenses


84,101


24,441

Deferred revenue, current portion


4,131


1,746

Current portion of long-term debt, net


99,048


89,419

Total current liabilities


199,512


117,147






Deferred revenue, net of current portion


2,739


2,530

Long-term debt, net


1,147,129


787,255

Other long-term liabilities


5,551


544

Deferred tax liabilities, net


3,288


?

Contingent liability


130,000


?






Stockholders' equity:





Common stock


138


138

Additional paid-in capital


271,169


256,347

Accumulated other comprehensive loss


(2,017)


(620)

Retained earnings (accumulated deficit)


23,881


(58,912)

Total stockholders' equity


293,171


196,953

Total liabilities and stockholders' equity


$      1,781,390


$       1,104,429

 

Halozyme Therapeutics, Inc.

GAAP to Non-GAAP Reconciliations

Net Income and Diluted EPS

(Unaudited)

(In thousands, except per share amounts)






Three Months Ended

 June 30,



2022


2021

GAAP Net Income


$        22,685


$            91,458

Adjustments:





Share-based compensation


5,635


5,372

Amortization of debt discount


1,112


965

Amortization of intangible assets


11,403


?

Transaction costs for business combinations(1)


18,593


?

Severance and share-based compensation acceleration expense(2)


22,552


?

Amortization of inventory step-up at fair value(3)


4,454


?

Realized loss from marketable securities(4)


1,727


?

Income tax effect of above adjustments(5)


(12,432)


(4)

Non-GAAP Net Income


$        75,729


$            97,791






GAAP Diluted EPS


$             0.16


$                0.62

Adjustments:





Share-based compensation


0.04


0.04

Amortization of debt discount


0.01


0.01

Amortization of intangible assets


0.08


?

Transaction costs for business combinations(1)


0.13


?

Severance and share-based compensation acceleration expense(2)


0.16


?

Amortization of inventory step-up at fair value(3)


0.03


?

Realized loss from marketable securities(4)


0.01


?

Income tax effect of above adjustments(5)


(0.09)


?

Non-GAAP Diluted EPS


$             0.53


$                0.66






GAAP & Non-GAAP Diluted Shares


142,216


147,624






Dollar amounts, as presented, are rounded. Consequently, totals may not add up.

(1)

Amount represents incremental costs including legal fees, accounting fees and advisory fees incurred for the Antares acquisition.

(2)

Amount represents severance cost and acceleration of unvested equity awards as part of the Antares merger agreement.

(3)

Amount related to amortization of the inventory step-up associated with purchase accounting for the Antares acquisition.

(4)

Amount represents realized loss from the sale of our marketable securities to finance the acquisition of Antares.

(5)

Estimated income tax effect of the Non-GAAP reconciling items are calculated using applicable statutory tax rates, taking into consideration of any valuation allowance.

 

Halozyme Therapeutics, Inc

GAAP to Non-GAAP Reconciliations

Net Income and Diluted EPS 2022 Guidance

(Unaudited)

(In millions, except per share amounts)




2022


2021

GAAP Net Income


$                  170 - 195


$                           402.7

Adjustments:





Inducement expense related to convertible notes


?


21.0

Share-based compensation


24 - 25


20.8

Amortization of debt discount


5 - 5


3.9

Amortization of intangible assets


65 - 65


?

Transaction costs for business combinations


21 - 21


?

Severance and share-based compensation acceleration expense


23 - 23


?

Amortization of inventory step-up at fair value


16 - 16


?

Realized loss from marketable securities


2 - 2



Income tax benefit


?


(154.2)

Income tax effect of above adjustments


(31) - (32)


(0.1)

Non-GAAP Net Income


$                   295 -320


$                           294.1






GAAP Diluted EPS


$                1.20 - 1.35


$                             2.74

Adjustments:





Inducement expense related to convertible notes


?


0.14

Share-based compensation


0.17 - 0.18


0.14

Amortization of debt discount


0.04 - 0.04


0.03

Amortization of intangibles


0.46 - 0.46


?

Transaction costs for business combinations


0.15 - 0.15


?

Severance and share-based compensation acceleration expense


0.16 - 0.16


?

Amortization of inventory step-up at fair value


0.11 - 0.11


?

Realized loss from marketable securities


0.01 - 0.01


?

Income tax benefit


?


(1.05)

Income tax effect of above adjustments


(0.22) - (0.22)


?

Non-GAAP Diluted EPS


$                2.10 - 2.25


$                             2.00






GAAP & Non-GAAP Diluted Shares


141.5 - 142.5


146.8






Dollar amounts, as presented, are rounded. Consequently, totals may not add up.

 

Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.) (PRNewsfoto/Halozyme Therapeutics, Inc.)

SOURCE Halozyme Therapeutics, Inc.


These press releases may also interest you

at 15:56
Some of the country's most influential leaders in urban redevelopment and neighborhood transformation will meet in Fort Myers for a convening of Choice Neighborhood Initiative Planning and Implementation grantees. The conference titled, Choice MEANS...

at 15:54
Investor Relations and Financial Communications firm Pedrosa Richardson started trading internationally from London today, with the purpose of supporting leading, global listed companies....

at 15:53
Rally House seizes the opportunity when there's a chance to provide an enhanced selection of team gear and localized merch to fans. That's why the company is ecstatic to announce a major expansion for Rally House East Lansing. This upgrade allowed...

at 15:49
Provident Bancorp, Inc. (the "Company") , the holding company for BankProv (the "Bank"), provided an update regarding developments related to crypto firm BlockFi....

at 15:41
Cincinnati has welcomed a handful of new Rally House stores this year, and the company is pleased to debut yet another in this market. Rally House Montgomery Road resides just northeast of the downtown area, giving fans in this part of the city a...

at 15:27
Conservation Labs today announced it has been selected to participate in the AWS Sustainable Cities Accelerator for Infrastructure, a technical, business, and mentorship program for startups seeking to use Amazon Web Services (AWS) to make...



News published on 9 august 2022 at 16:01 and distributed by: